<DOC>
	<DOCNO>NCT00999167</DOCNO>
	<brief_summary>This phase 2 study HPN-100 subject hepatic encephalopathy ( HE ) consist open label safety lead-in ( Part A ) , follow randomize , double-blind , placebo-controlled treatment ( Part B ) .</brief_summary>
	<brief_title>A Study Safety Efficacy HPN-100 Subjects With Cirrhosis Episodic Hepatic Encephalopathy</brief_title>
	<detailed_description>Part A : Open-label , dose-escalation lead-in ass HPN-100 safety PK Approximately 10 subject HE cirrhosis classify Child Pugh B C undergo one-step dose escalation 4 week . Subjects initially receive 6 mL HPN-100 BID 1 week . On Day 7 follow satisfactory safety assessment subject , dose escalate 9 mL BID additional 3 week . In addition safety assessment , subject undergo 12-hour PK assessment Days 7 28 , sample follow time point ( relative first dose ) : 0 ( pre-first daily dose HPN-100 ) , 2 , 4 , 8 ( approximately 2 hour second daily dose HPN 100 ) , 12 hour post-first dose ( approximately 2 hour second daily dose HPN-100 ) . Additional PK sample collect Days 8 , 15 , 21 ( pre-first dose 4 hour post-first dose ) . The DSMB review safety information , include laboratory value , determine Part B may initiate . Subjects enrol Part A may eligible Part B long meet eligibility criterion . Part B : Randomized , double-blind assessment HPN-100 HE subject Subjects meet entry criterion judge compliant prescribed SOC eligible randomization receive either HPN-100 matching placebo 16 week . Efficacy assess proportion subject experience episode HE , well outcome measure , include daily home assessment .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<mesh_term>Glycerol</mesh_term>
	<criteria>Subjects age 18 Clinical diagnosis cirrhosis cause Potential benefit HE treatment History great equal 2 document episode WH Grade 2 HE within past 6 month , least one occur within precede 3 month No change HEspecific medication within 1 week randomization Able give inform consent comply study activity Availability least one designate family member caregiver capable willing assume responsibility facilitate subject compliance study procedures All female childbearing age sexually active male must agree use acceptable method contraception throughout study . Use investigational drug within 30 day Use prohibit medication Uncontrolled infection Active GI bleed history GI bleed require blood transfusion ( &gt; 2 unit ) within 3 month Transjugular intrahepatic portosystemic shunt ( TIPS ) placement revision within past 90 day Recreational drug use alcohol consumption subject history alcohol drug abuse within 6 month Lactating and/or pregnant female Active malignancy Clinically significant bowel disease , include obstruction , inflammatory bowel disease , malabsorption Expected undergo transplantation within 6 month Model endstage liver disease ( MELD ) score &gt; 25</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Cirrhosis</keyword>
	<keyword>Episodic Hepatic Encephalopathy</keyword>
	<keyword>HE</keyword>
	<keyword>HPN-100</keyword>
	<keyword>GT4P</keyword>
	<keyword>glycerol phenylbutyrate</keyword>
</DOC>